Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs

Arthritis Care and Research

Volumn 55, Issue 4, 2006, Pages 537-542

  Mosis, Georgio ^a   Stijnen, Theo ^a   Castellsague, Jordi ^b   Dieleman, Jeanne P ^a   Van Der Lei, Johan ^a   Stricker, Bruno H C ^a   Sturkenboom, Miriam C J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PFIZER INC   (United States)

Author keywords

Cardiovascular; Channeling; COX 2 selective inhibitors; Gastrointestinal; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; INOTROPIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; DIGESTIVE SYSTEM ULCER; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG USE; DUODENITIS; DUODENUM DISEASE; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MUSCULOSKELETAL DISEASE; NETHERLANDS; OSTEOARTHRITIS; PEPTIC ULCER; POPULATION DYNAMICS; PRESCRIPTION; PREVALENCE; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH DISEASE; TREATMENT CONTRAINDICATION;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CHILD; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; PREVALENCE; PROBABILITY; RESEARCH SUPPORT; RISK ASSESSMENT;

EID: 33747874024     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22096     Document Type: Article

References (22)

1. Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996;312:1563-6.
2. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal antiinflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98-101.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al, and the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343: 1520-8.
4. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
5. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al, and the Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
6. Fomer H. NHG-Standpunt over de preventie van NSAID-geinduceerde maagproblemen en de plaats van de coxibs in de huisartspraktijk. 2004. URL: http://nhg.artsennet.nl/ content/resources/AMGATE_6059_104_TICH_L1297846793/ AMGATE_6059_104_TICH_R120544452391946//.
7. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
8. National Institute for Health and Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: NICE; 2001.
9. Lenzer J. FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 2005;330:440.
10. European Medicines Agency. URL: http://www.emea.eu.int/ htms/hotpress/d6275705.htm.
11. LeLorier J, Fitzsimon C, Keresteci M, Stewart D, Lavoie F. Drug utilization review of celecoxib in Ontario. Rheumatology (Oxford) 2003;42 Suppl 3:iii11-6.
12. Dai C, Stafford RS, Alexander GC. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005;165:171-7.
13. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
14. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360: 1071-3.
15. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
16. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005;165:181-6.
17. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittarns J, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
18. MacDonald TM, Pettitt D, Lee FH, Schwartz JS. Channelling of patients taking NSAIDs or cyclooxygenase-2-specific inhibitors and its effect on interpretation of outcomes. Rheumatology (Oxford) 2003;42 Suppl 3:iii3-10.
19. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339-44.
20. Solomon DH, Avorn J. Coxibs, science, and the public trust. Arch Intern Med 2005;165:158-60.
21. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 2005;58:98-102.
22. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003;115:715-20.